Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar ...
Novo Nordisk A/S is closing in on Eli Lilly in the GLP-1 market despite Ozempic declines. Click for this NVO stock update.
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
The revised framework directs drug inspectors to prepare monthly and annual sampling plans covering the entire jurisdiction.
TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial highlights — delivered at 10 pm.
Eli Lilly said on Tuesday it will buy three vaccine developers in deals worth up to $3.8 billion in combined value, ...
The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr ...
Shares of Eli Lilly rose 0.9% shortly after the market opened. "These acquisitions reflect a deliberate strategy to prevent ...
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an ...
Novo Nordisk is aiming to rewrite the trajectory of its GLP-1 franchise by bringing semaglutide into a neglected liver disease, as fresh data from Barcelona reinforce the drug’s potential beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results